A Study Of Early Markers Of Choroidal Neovascularization
NCT ID: NCT00902785
Last Updated: 2010-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
100 participants
OBSERVATIONAL
2008-03-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
no drug
no drug
no drug
observational no drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no drug
observational no drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No CNV or geographic atrophy in the study eye.
* Best corrected visual acuity in the study eye of greater than 20/40 or better than 70 ETDRS letters.
* Sufficiently clear ocular media and adequate pupillary dilatation to permit good quality fundus imaging of the study eye.
* Subjects of either sex, aged 50 years.
* Evidence of a signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial.
* Willing and able to comply with scheduled visits, laboratory tests, and other trial procedures.
Exclusion Criteria
* Evidence of manifest CNV by FA, color photography or ICG angiography in the study eye.
* Any prior treatment for CNV to the study eye (excluding vitamins and AREDS formula).
* Significant media opacities, including cataract, which might interfere with visual acuity assessments, or fundus imaging in the study eye. Subjects should not be entered if there is likelihood that they will require cataract surgery within the following 2 years.
* Presence of other causes of choroidal neovascularization in the fellow eye, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25 mm or more), the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis.
* Any progressive eye disease other than AMD (eg, glaucoma, diabetic retinopathy) in the study eye.
* Presence of subretinal hemorrhage, serous or hemorrhagic pigment epithelial detachments, subretinal fibrosis or pigment epithelial tears or rips in the study eye.
* Any medical condition that would interfere with the patient's ability to complete the trial.
* Concurrent enrollment in any other observational or interventional clinical study.
* Any treatment with an ocular or systemic investigational agent in the past 60 days for any medical condition.
* Known serious allergies to the dye used in fluorescein angiography or ICG.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Belfast, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A9011051
Identifier Type: -
Identifier Source: org_study_id